| |  Online-Ressource |
|---|
| Verfasst von: | Korell, Felix [VerfasserIn]  |
|---|
| | Schönland, Stefan [VerfasserIn] |
|---|
| | Schmitt, Anita [VerfasserIn] |
|---|
| | Jansen, Madelaine [VerfasserIn] |
|---|
| | Farid, Kiavasch [VerfasserIn] |
|---|
| | Müller-Tidow, Carsten [VerfasserIn] |
|---|
| | Dreger, Peter [VerfasserIn] |
|---|
| | Schmitt, Michael [VerfasserIn] |
|---|
| | Hegenbart, Ute [VerfasserIn] |
|---|
| Titel: | First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma |
|---|
| Verf.angabe: | Felix Korell, Stefan Schönland, Anita Schmitt, Madelaine Jansen, Kiavasch Farid, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt and Ute Hegenbart |
|---|
| E-Jahr: | 2023 |
|---|
| Jahr: | 14 October 2023 |
|---|
| Umfang: | 5 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Veröffentlicht: 14. Oktober 2023 ; Gesehen am 14.12.2023 |
|---|
| Titel Quelle: | Enthalten in: Biomarker Research |
|---|
| Ort Quelle: | London : Biomed Central, 2013 |
|---|
| Jahr Quelle: | 2023 |
|---|
| Band/Heft Quelle: | 11(2023), Artikel-ID 91, Seite 1-5 |
|---|
| ISSN Quelle: | 2050-7771 |
|---|
| Abstract: | Light chain amyloidosis (AL) is a rare disease caused by the generalized deposition of misfolded free light chains. Patients with immunoglobulin M gammopathy (IgM) and indolent B-cell lymphoma such as marginal zone lymphoma (MZL) may in some instances develop AL amyloidosis. So far, CAR T cells for AL amyloidosis have only been reported utilizing the B cell maturation antigen as target, while CD19 has so far not been used in AL amyloidosis. We report the case of a 71-year-old male, diagnosed with systemic AL kappa amyloidosis and MZL, receiving third-generation CAR T cell therapy targeting CD19. Prior treatment included bendamustine/rituximab and cyclophosphamide/ dexamethasone with subsequent autologous stem cell transplantation. CAR T application was well tolerated despite heart and kidney amyloid manifestations, and only early low-grade procedure-specific toxicities were observed. A continuous decrease in IgM, kappa light chains and kappa-to-lambda light chain difference was observed in the patient from day + 30 on, resulting in a deep hematological response six months after treatment. In summary, we present a novel case of CAR T cell treatment with third generation CD19 directed infusion for AL amyloidosis with an underlying secretory active B cell lymphoma, showing that this is an effective treatment modality and can be applied to patients with subsequent AL amyloidosis. |
|---|
| DOI: | doi:10.1186/s40364-023-00532-2 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.1186/s40364-023-00532-2 |
|---|
| | DOI: https://doi.org/10.1186/s40364-023-00532-2 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Amyloidosis |
|---|
| | CAR T cell therapy |
|---|
| | Free light chains |
|---|
| | IgM |
|---|
| | Marginal zone lymphoma |
|---|
| K10plus-PPN: | 1875701753 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma / Korell, Felix [VerfasserIn]; 14 October 2023 (Online-Ressource)
